Magnasense logotype


Brand Change Announcement: AegirBio AB has officially changed its name to Magnasense AB. The new website,, launched on 9 July 2024, with redirects from

Interview with AegirBio CEO Mr Marco Witteveen

AegirBio CEO, Marco Witteveen, recently conducted an interview in Stockholm on the company's current position and strategic outlook.

During the interview, Mr. Witteveen emphasized the pivotal juncture the company finds itself in, asserting that the leadership team has a clear vision of the path ahead. The company is set on a course focused on the market opportunities in Therapeutic Drug Monitoring and Oral Health. These areas, he stressed, not only hold significant clinical, operational, and economic potential but also promise to enhance the offerings available in today's market.

Mr. Witteveen underscored the combination of in-house expertise and unwavering drive that propels the company forward. Additionally, he highlighted the robust organizational culture that has been nurtured within the company, one that resonates with both our team members and the broader market. This unique blend of factors, complemented by a strategic public relations approach, positions us in the market.

We believe that this interview encapsulates the essence of our company's strategic vision and reinforces our commitment to delivering innovative solutions that create substantial value in the healthcare industry. Please check the link,,  for the full interview

About Aegirbio

AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website

The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 |

Related link: